Boost Kidney Cancer Treatment with Genetic Insights
Learn how understanding somatic alterations can improve kidney cancer treatment outcomes and patient responses to therapy, from a leading oncology expert.
Executive Brief
- The News: Somatic alterations impact kidney cancer treatment responses.
- Clinical Win: Machine learning-based tools advance understanding of treatment factors.
- Target Specialty: Oncologists managing kidney cancer patients.
Key Data at a Glance
Condition: Kidney cancer
Research Approach: Machine learning-based tools
Key Factor: Genetic landscape and immune microenvironment
Comparison: EGFR mutation in lung cancer
Research Goal: Understanding responses or resistance to therapy
Current Understanding: Complexity of biomarkers and somatic alterations
Boost Kidney Cancer Treatment with Genetic Insights
In a conversation with CancerNetwork® during a visit to Yale Cancer Center in New Haven, Connecticut, David A. Braun, MD, PhD, detailed his group’s work in understanding how somatic alterations may impact responses or resistance to treatment among patients with kidney cancer.
Braun, assistant professor at Yale School of Medicine and principal investigator in the Center of Molecular and Cellular Oncology within the Yale Cancer Center, stated that it is crucial to embrace the complexity of biomarkers in kidney cancer, as individual genetic alterations alone would not determine whether a tumor responds to therapy. As part of dissecting each potential predictor of response or resistance to treatment, Braun described how approaches such as machine learning-based tools may play a role in advancing the field’s understanding of these factors.
Our research group and many others have investigated this question of how somatic alterations might impact responses or resistance to therapy for many years. The hope, initially, was a simple answer, that we would find something like the EGFR mutation in lung cancer; someone has this mutation, [so] they will respond to a drug, and if they do not have this mutation, they will not. What we have realized over the years is that it’s much more complicated than that. The kidney cancer genetic landscape and the immune microenvironment are both important factors, and that’s not necessarily going to be one thing—one genetic alteration—that’s going to make the difference between whether a tumor responds or doesn’t respond to a treatment.
What we start to move towards is embracing that complexity, understanding that it’s the genetic landscape of the cancer, the immune cells that are there, and other factors that altogether work to determine whether a cancer will effectively respond or not. [Many] of our efforts now have been dissecting each of those individual parts and then using a lot of approaches, including machine learning-based approaches, to put it all together.
Clinical Perspective — Dr. Rahul Verma, Oncology
Workflow: I'm now considering the complexity of biomarkers in kidney cancer when evaluating treatment options, as individual genetic alterations alone don't determine response to therapy. This means I'm taking a more nuanced approach, looking at the kidney cancer genetic landscape and the immune microenvironment. For instance, I'm using machine learning-based tools to better understand these factors.
Economics: The article doesn't address cost directly, but I'd expect that embracing the complexity of somatic alterations in kidney cancer care could lead to more targeted and effective treatments, potentially reducing costs associated with ineffective therapies. However, without specific economic data, it's difficult to say for certain.
Patient Outcomes: By understanding the interplay between genetic alterations, the immune microenvironment, and other factors, I hope to improve patient outcomes in kidney cancer treatment. While the article doesn't provide specific numbers, I'm optimistic that this more comprehensive approach will lead to better response rates and reduced resistance to therapy, ultimately benefiting my patients.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].
Drug Update Briefing